Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by J. E. Rosenberg
Closure of the fascial defect during laparoscopic umbilical hernia repair: a randomized clinical trial
Background The objective of the study was to analyse patient‐reported outcome measures (PROMs), seroma formation, long‐term recurrence and chronic pain after closure of the fascial defect in patients undergoing laparoscopic umbilical hernia mesh repair. Methods This was a randomized double‐blinded trial in patients undergoing elective laparoscopic umbilical hernia repair comparing sutured closure of the fascial defect before intraperitoneal onlay mesh (IPOM) repair with a no‐closure IPOM repair.
Network meta‐analysis of urinary retention and mortality after Lichtenstein repair of inguinal hernia under local, regional or general anaesthesia
Abstract en Background Urinary retention and mortality after open repair of inguinal hernia may depend on the type of anaesthesia. The aim of this study was to investigate possible differences in urinary retention and mortality in adults after Lichtenstein repair under different types of anaesthesia. Methods Systematic searches were conducted in the Cochrane, PubMed and Embase databases, with the last search on 1 August 2018.
British Journal of Dermatology
黑色素瘤是最致命的皮肤癌。本次研究在澳大利亚进行,在该国 2016 年有 1,281 人死于黑色素瘤。近几年,随着免疫和靶向治疗技术的引入,黑色素瘤治疗快速变化。因此使某些患者生存期延长,但这些治疗对哪些患者有效,以及有效时间多长尚不明确。本次研究旨在了解黑色素瘤治疗对家属照顾者的经验的影响,因为治疗与诊断和预后相关。对在3个澳大利亚黑色素瘤中心接受治疗并随后死亡的患者的20名照顾者进行了访谈。研究发现,晚期黑色素瘤的诊断有一段不确定时间,因为照顾者努力了解诊断的含义。相对较新的免疫和靶向治疗形式的治疗选项为预后增加了不确定性(即,可能的结局,如存活几率)。照顾者称与医疗专家就预后的沟通不明确。某些照顾者称医疗专家不想或无法提供预后描述。许多照顾者期望治疗会有积极的结局。研究结果显示,医疗专家应该在诊断后尽早识别并解决照顾者对预后信息的了解和需求。就上述新疗法针对不确定疗效的沟通会帮助患者和照顾者对治疗首选项和照顾计划进行决策。
Qualitative study of bereaved carers’ experiences in advanced melanoma
Plain Language Summary Qualitative study of bereaved carers’ experiences in advanced melanoma PDF PDF Share Summary Melanoma is the deadliest form of skin cancer. In Australia, where this study was conducted, there were 1,281 deaths from melanoma in 2016. Treatments for melanoma have changed rapidly in recent years with the introduction of immune and targeted therapies.
Novel Therapies in Urothelial Carcinoma
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel In This Article Abstract and Introduction Abstract Urothelial malignancies, including carcinomas of the bladder, ureters, and renal pelvis comprised ~8% of new cancer cases in the USA in 2016.
Uncertain diagnosis and prognosis in advanced melanoma: A qualitative study of the experiences of bereaved carers in a time of immune and targeted therapies - Fox - - British Journal of Dermatology - Wiley Online Library
Background Recent advances in advanced melanoma therapies are associated with improved survival for some patients. How patients with diagnoses of advanced disease and their carers experience this expanding treatment paradigm, however, is not well understood. Objectives We explored bereaved carers’ accounts of the trajectory of advanced melanoma involving treatment by immune or targeted therapies to build an understanding of their experiences of care relating to diagnosis and prognosis.
Two‐year results of the randomized clinical trial DILALA comparing laparoscopic lavage with resection as treatment for perforated diverticulitis
The aim of the present study was to compare outcomes after laparoscopic lavage versus Hartmann's procedure in the DILALA trial, in terms of the proportion of patients who required one or more further operations, as well as admission rates, within 2 years of index surgery. Laparoscopic lavage as an alternative to these procedures was reported to have promising results 6 and has now been investigated in three RCTs 7 - 10 .
Two‐year results of the randomized clinical trial DILALA comparing laparoscopic lavage with resection as treatment for perforated diverticulitis
The aim of the present study was to compare outcomes after laparoscopic lavage versus Hartmann's procedure in the DILALA trial, in terms of the proportion of patients who required one or more further operations, as well as admission rates, within 2 years of index surgery. Laparoscopic lavage as an alternative to these procedures was reported to have promising results 6 and has now been investigated in three RCTs 7 - 10 .
Two‐year results of the randomized clinical trial DILALA comparing laparoscopic lavage with resection as treatment for perforated diverticulitis
Traditionally, perforated diverticulitis with purulent peritonitis was treated with resection and colostomy (Hartmann's procedure), with inherent complications and risk of a permanent stoma. The DILALA (DIverticulitis – LAparoscopic LAvage versus resection (Hartmann's procedure) for acute diverticulitis with peritonitis) and other randomized trials found laparoscopic lavage to be a feasible and safe alternative. The medium‐term follow‐up results of DILALA are reported here.
Endothelial dysfunction in the early postoperative period after major colon cancer surgery
Background. Evidence suggests that endothelial dysfunction in the early postoperative period promotes myocardial injury after non-cardiac surgery. The aim of this study was to investigate the impact of colon cancer surgery on endothelial function and the association with the l-arginine-nitric oxide pathway postoperatively. Methods. Patients undergoing elective colon cancer surgery (n?=?31) were included in this prospective observational cohort study.
Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study
Background: Nivolumab has shown promising efficacy and acceptable safety in an open-label, multicenter phase I/II study in patients (pts) with mUC after ?1 prior platinum-based therapy (NCT01928394). Here we report updated efficacy and safety results for the overall population based on additional follow-up and outcomes by differing levels of PD-L1 expression. Methods: Pts with mUC, unselected by PD-L1 expression status, received nivolumab 3 mg/kg IV every 2 wk until progression or discontinuation.
Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study
Background: Plat-refractory mUC pts have no therapies that significantly extend OS, which is < 7 mo in the 2L setting (Bellmunt J Clin Oncol 2009). Atezo (anti-PDL1) has demonstrated tolerability and efficacy in plat-treated mUC. Here we present updated data on pts with ? 1.5-y median follow-up (mFU). Methods: Pts who had progressed during/following plat received 1200 mg atezo IV q3w and could continue treatment past RECIST v1.1 PD until loss of clinical benefit.
Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC)
Background: Nectin-4 is a protein expressed on several tumors, including mUC. Enfortumab vedotin is an ADC that delivers a small molecule microtubule-disrupting agent, monomethyl auristatin E (MMAE), to tumors expressing Nectin-4. Methods: Pts with solid tumors, including mUC, treated with ? 1 prior chemo were enrolled using a modified continual reassessment method design. Pts were prescreened for Nectin-4 expression (IHC assay) and enrolled if H-score ?150.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with J. E.
Contact J. E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack